ResearcherHokkaido UniversityActive in the last 2 years
Shigeru Hashimoto
Matched on OpenAlex author ID A5015886026. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 1, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 7
2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 2 papers · 2023: none · 2024: 1 paper
Papers 6
- Plasticity and Tumor Microenvironment in Pancreatic Cancer: Genetic, Metabolic, and Immune Perspectives. First author DOI 10.3390/cancers16234094↗
- ARF6-AMAP1 pathway induces pancreatic cancer cells to express immunosuppressive chemokines Co-author DOI 10.21203/rs.3.rs-1897319/v1↗
- Orchestration of mesenchymal plasticity and immune evasiveness via rewiring of the metabolic program in pancreatic ductal adenocarcinoma. Last author DOI 10.3389/fonc.2022.1005566↗
- Inhibition of mutant KRAS-driven overexpression of ARF6 and MYC by an eIF4A inhibitor drug improves the effects of anti-PD-1 immunotherapy for pancreatic cance… Co-author DOI 10.1186/s12964-021-00733-y↗
- High expression of AMAP1, an ARF6 effector, is associated with elevated levels of PD-L1 and fibrosis of pancreatic cancer. Co-author DOI 10.1186/s12964-020-00608-8↗
- ARF6 and AMAP1 are major targets of KRAS and TP53 mutations to promote invasion, PD-L1 dynamics, and immune evasion of pancreatic cancer. Co-author DOI 10.1073/pnas.1901765116↗
Closest collaborators
The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Ari Hashimoto · 6 shared papers, 2019–2024 · strength 1.16
- Paper Plasticity and Tumor Microenvironment in Pancreatic Cancer: Genetic, Metabolic, and Immune Perspectives. DOI 10.3390/cancers16234094↗
- Paper Orchestration of mesenchymal plasticity and immune evasiveness via rewiring of the metabolic program in pancreatic duct… DOI 10.3389/fonc.2022.1005566↗
- Paper ARF6-AMAP1 pathway induces pancreatic cancer cells to express immunosuppressive chemokines DOI 10.21203/rs.3.rs-1897319/v1↗
- Akio Tsutaho · 4 shared papers, 2019–2022 · strength 0.48
- Paper ARF6-AMAP1 pathway induces pancreatic cancer cells to express immunosuppressive chemokines DOI 10.21203/rs.3.rs-1897319/v1↗
- Paper Inhibition of mutant KRAS-driven overexpression of ARF6 and MYC by an eIF4A inhibitor drug improves the effects of anti… DOI 10.1186/s12964-021-00733-y↗
- Paper High expression of AMAP1, an ARF6 effector, is associated with elevated levels of PD-L1 and fibrosis of pancreatic canc… DOI 10.1186/s12964-020-00608-8↗
- Hisataka Sabe · 4 shared papers, 2019–2022 · strength 0.48
- Paper ARF6-AMAP1 pathway induces pancreatic cancer cells to express immunosuppressive chemokines DOI 10.21203/rs.3.rs-1897319/v1↗
- Paper Inhibition of mutant KRAS-driven overexpression of ARF6 and MYC by an eIF4A inhibitor drug improves the effects of anti… DOI 10.1186/s12964-021-00733-y↗
- Paper High expression of AMAP1, an ARF6 effector, is associated with elevated levels of PD-L1 and fibrosis of pancreatic canc… DOI 10.1186/s12964-020-00608-8↗
- Satoshi Hirano · 4 shared papers, 2019–2022 · strength 0.48
- Paper ARF6-AMAP1 pathway induces pancreatic cancer cells to express immunosuppressive chemokines DOI 10.21203/rs.3.rs-1897319/v1↗
- Paper Inhibition of mutant KRAS-driven overexpression of ARF6 and MYC by an eIF4A inhibitor drug improves the effects of anti… DOI 10.1186/s12964-021-00733-y↗
- Paper High expression of AMAP1, an ARF6 effector, is associated with elevated levels of PD-L1 and fibrosis of pancreatic canc… DOI 10.1186/s12964-020-00608-8↗
- Yoshihiro Nishikawa · 2 shared papers, 2019–2022 · strength 0.22
- Yuzo Kodama · 2 shared papers, 2019–2022 · strength 0.22
- Yusuke Mizukami · 1 shared paper, 2019 · strength 0.07
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.